Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial   (2025-12-11)
The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill.